Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 62, Issue 4, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01971-17
Keywords
lascufloxacin; Streptococcus pneumoniae; fluoroquinolone resistance
Categories
Funding
- Kyorin Pharmaceutical Co., Ltd.
- Ministry of Health, Labor and Welfare, Japan [H28-Shinkou-Ippan-003]
- Japan Agency for Medical Research and Development (AMED)
Ask authors/readers for more resources
Lascufloxacin showed potent activity against Streptococcus pneumoniae with a GyrA or ParC mutation (first-step mutant). The frequency of selecting resistant strains tended to be lower for lascufloxacin than for levofloxacin and garenoxacin after drug exposure in first-step mutants but was similar in the comparison between lascufloxacin and moxifloxacin. The increase in MIC was smaller for lascufloxacin than for levofloxacin, garenoxacin, and moxifloxacin when clinical strains with only ParC mutations were exposed to the corresponding drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available